Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Clovis Oncology

Evaluate

Thumbnail
June 03, 2023

Asco 2023 – a role for immuno-oncology in ovarian cancer at last?

Astra’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.

May 02, 2023

The sellside hacks back Lynparza’s prostate opportunity

The writing had been on the wall for Parp inhibitors in first-line prostate cancer, and last week’s US panel showed no mercy.

Article image
Vantage logo
April 26, 2023

Point looks to turn the tables on Novartis

Conventional wisdom says manufacturing takes second place to clinical development, but Point turned that on its head, and now a big catalyst approaches.

Article image
Vantage logo
February 17, 2023

Asco-GU – Talzenna remains a wait-and-see story in prostate cancer

Talapro-2 data backing Talzenna in all-comers are slated by Asco-GU’s discussant, as Lynparza shows precisely what might go wrong.

Article image
Vantage logo
December 12, 2022

Clovis's story ends at chapter 11

Article image
Vantage logo
November 11, 2022

The Parp retreat begins

Article image
Vantage logo
November 09, 2022

Merrimack shows how to survive and reward investors; Clovis not so much

Article image
Vantage logo
October 05, 2022

Pfizer reignites the Parp biomarker debate

Talzenna scores in first-line prostate cancer irrespective of HRR status, but for now we only have Pfizer’s word for it.

Article image
Vantage logo
October 03, 2022

FDA scrutiny now hits Parp inhibitors

A November adcom could decide whether Zejula will lose yet more ground to Lynparza.

Article image
Vantage logo
October 03, 2022

Rubraca’s pyrrhic prostate cancer win

Article image
Vantage logo
September 14, 2022

Esmo 2022 movers – Kras backfires

Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up